Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  by Logan, Brent R. et al.
R
V
i
I
d
t
s
f
d
s
o
a
t
s
f
a
s
c
e
f
e
i
p
r
i
Biology of Blood and Marrow Transplantation 12:107-112 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1201-0119$32.00/0
doi:10.1016/j.bbmt.2005.09.005
Begression Models for Hazard Rates
ersus Cumulative Incidence Probabilities
n Hematopoietic Cell Transplantation Data
Brent R. Logan, Mei-Jie Zhang, John P. Klein
Division of Biostatistics and Center for International Blood and Marrow Transplant Research, Medical College of
Wisconsin, Milwaukee, Wisconsin
Correspondence and reprint requests: John P. Klein, PhD, Division of Biostatistics, Medical College of Wisconsin,
Milwaukee, WI (e-mail: klein@hpi.mcw.edu).
ABSTRACT
In this article, we consider methods of regression modeling in the competing risks setting commonly encoun-
tered in analyzing stem cell transplantation data. We clarify the distinction between modeling the cause-
specific hazard rate and modeling the cumulative incidence probability or function, and we review regression
techniques for both types of quantities. We apply them to 2 examples: 1 comparing engraftment and 1
examining relapse. These examples illustrate that different conclusions may result depending on the type of
regression model used for comparing treatments. Finally, we show how these discrepancies occur because 2
different characteristics of the time-to-event distribution are being modeled.
© 2006 American Society for Blood and Marrow Transplantation
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Analyses of hematopoietic cell transplantation
ata are typically performed on several outcomes after
ransplantation, including death, relapse or progres-
ion, engraftment, graft-versus-host-disease, and in-
ection. The analysis of some of these events, such as
eath or treatment failure (relapse or death), is
traightforward, and techniques for analyzing these
utcomes are reviewed in Klein et al. [1] and Klein
nd Moeschberger [2]. Other events—such as relapse,
reatment-related mortality, and engraftment—are
ubject to competing risks. Competing risks are events
or which the occurrence of some other event does not
llow the event to occur. For example, death in remis-
ion and relapse are competing risks because the oc-
urrence of 1 precludes the occurrence of the other
vent. Censoring and competing risks are often con-
used. When a patient is censored, he or she could still
xperience the event after the censoring time, and the
nterest is on making inferences about patients in
ractice who are not subject to censoring. Competing
isks, conversely, prevent the person from experienc-
ng the event of interest. Inference here is on the r
B&MThance of the event occurring in patients who could
xperience any of the risks.
Outcomes happen at various times after transplan-
ation and may be subject to competing risks. Most
ommonly, analyses include (1) descriptive statistics
uch as the Kaplan-Meier curve for death or treatment
ailure or the cumulative incidence curve for compet-
ng risks and (2) simple univariate comparisons of 2 or
ore groups of patients by using the log-rank test
r a comparison of survival or cumulative incidence
robabilities at a ﬁxed point in time. Sometimes in-
estigators may be interested in identifying risk factors
or a particular outcome or in comparing groups of
atients after adjusting for important prognostic fac-
ors. The most commonly used regression model for
nalyzing event-time data is the Cox proportional
azards model [3], reviewed in the context of hema-
opoietic cell transplantation data by Klein et al. [4].
he Cox model is a regression model for the hazard
ate, or instantaneous risk, of a given outcome. It is
ften used in the presence of competing risks to model
he cause-speciﬁc hazard rate, which is the rate at which
atients yet to experience either competing risk expe-
ience the event of interest. When the outcome is a
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1eath or treatment failure, there is a 1 to 1 correspon-
ence between the hazard rate and the survival prob-
bility as estimated by the Kaplan-Meier estimator.
or competing risks data, this relationship does not
old, and estimates of the probability that a patient
as experienced the event of interest, the cumulative
ncidence function, depend on the hazard rates for all
he competing risks. It is important to note that the
aplan-Meier estimator is not an appropriate statistic
hen there are competing risks because it estimates
he probability of the event occurring in an imaginary
atient who cannot experience the other events. For
xample, a Kaplan-Meier estimator of relapse is an
stimate of the probability of relapsing in a patient
ho can never die.
When the Cox model is used for death with cen-
ored data, we are modeling the rate at which patients
ould die if they were not at risk for censoring. This
s a consequence of the censoring being independent
f the event of interest. For competing risks, we math-
matically treat occurrences of the competing risks as
ensored observations, but the interpretation of these
odels is as rates of occurrence of the event of interest
n patients who could fail from either of the risks—not in
atients who could fail only from the cause of interest.
It is important to note that modeling the hazard
ate may or may not match the objective of the inves-
igator. For example, when studying engraftment, re-
earchers may be more interested in what proportion of
eople engraft by day 28 after transplantation rather
han how quickly they actually engraft, because differ-
nces in median times to engraftment may be only a
ouple of days and may not be clinically relevant.
herefore, the researcher must recognize the differ-
nce between a rate and a cumulative incidence prob-
bility of an event occurring when deciding on an
ppropriate regression analysis strategy.
The cumulative incidence of an event occurring by
speciﬁc time is a probability that depends on the
ccumulated hazards over time of both the event of
nterest and the competing risk. For example, the
robability of engrafting before day 28 includes the
robability of engrafting at day 1 or at day 2 or at day 3,
nd so forth. It depends on the rate at which patients
ngraft and the rate at which they experience the
ompeting risk, death. Note that when no patients are
ost to follow-up before time t, the cumulative inci-
ence function is simply the proportion of patients
ho experience the event before time t. For example,
f the outcome is day 28 engraftment or day 100
reatment-related mortality and all patients have com-
lete follow-up, then the cumulative incidence prob-
bility can be simply estimated as the number of
vents (eg, the number of people who engrafted by
ay 28 and before death) divided by the number of
eople in the study. For censored data, other standard b
08echniques are available for estimating the cumulative
ncidence curve [5-7].
The Cox model focuses on the rate at which events
ccur over time and not necessarily the cumulative inci-
ence of such events occurring. Although often the
nterpretation of the model will be similar regardless
f whether the hazard rate or the cumulative incidence
robability is modeled, in some cases it will not. For
xample, when comparing engraftment between 2
roups, 1 group may engraft faster (higher rate), but
oth treatment groups may have similar cumulative
ncidences of engraftment at day 28. Disparate results
an also occur between the outcomes when there is a
reatment effect on the competing event. This is be-
ause the cumulative incidence function depends on
oth the hazard rate for the event of interest and the
azard rate for the competing events, whereas the Cox
odel considers only the instantaneous hazard rate for
he event of interest. In this article, we review regres-
ion models for the rate of events and for the cumu-
ative incidence of events. We will apply them to 2
xamples to illustrate the discrepancies that may arise
n the results depending on the type of regression
odel used. We will show how these discrepancies
rise because 2 different characteristics of the time-
o-event distribution are being modeled.
EGRESSION MODELS FOR EVENT RATES
The Cox proportional hazards model expresses
he hazard rate for patient i as
hi(t) h0(t) exp(Zi)
ere h0(t) is a baseline hazard rate that we estimate
onparametrically, Zi is the ith patient’s covariate vec-
or, and  is the risk or regression coefﬁcient vector.
he risk coefﬁcient for a binary covariate (1 if the
atient has the condition and 0 otherwise) tells us
bout the relative risk for someone with that covariate
ersus a patient without that covariate. The relative
isk is exp(j); a relative risk of 2, for example, is
nterpreted as meaning that the instantaneous risk of
n event at any time for a patient with the covariate is
wice that of a patient without the covariate. The
og-rank test, commonly used in univariate analysis, is
special case of the Cox model and compares hazards
not probabilities). For continuous covariates, exp(j)
s interpreted as the relative risk associated with a
-unit change in the covariate.
Other issues surrounding the Cox model—such as
ime-varying effects, model checking, and stratiﬁca-
ion—are discussed in Klein et al. [4]. Furthermore,
ther models for the hazard rate exist, such as accel-
rated failure time models or additive models [8-10],
ut we do not discuss them further.
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Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities
BEGRESSION MODELS FOR CUMULATIVE
VENT PROBABILITIES
In this section, we consider alternatives to the
sual Cox regression in 2 competing risk scenarios
ommonly encountered in bone marrow (BM) trans-
lantation data analysis. The ﬁrst scenario is when the
ata are uncensored and interest is on the cumulative
ncidence probability at a ﬁxed time. This could occur,
or example, when one is interested in the cumulative
ncidence of engraftment by a speciﬁc early time point
hen follow-up is complete (eg, 28 days). Another ex-
mple would be if the researcher is interested in model-
ng the cumulative incidence of treatment-related mor-
ality at 100 days, again with complete follow-up. The
econd scenario discussed here is when the data are
ensored and the researcher is interested in comparing
he entire cumulative incidence curves between 2 treat-
ents, adjusting for covariates. This would occur, for
xample, when the researcher is interested in modeling
he cumulative incidence of relapse over time.
When the data are uncensored and interest is on
he cumulative incidence probability of a particular
vent at a ﬁxed time, the data for each individual
educe to a dichotomous outcome (1 if the patient
xperienced the event by that time and 0 if not). In
his case, logistic regression [11] can be used. Lo-
istic regression models the log odds of the cumu-
ative event probability for subject i, pi, as a linear
unction of the covariates:
log pi1 piZi
The risk coefﬁcient for a binary covariate  is
elated to the odds ratio (OR) through OR  exp();
his is interpreted as the OR of experiencing the event
y the ﬁxed time for someone with the covariate
ersus someone without the covariate. For a continu-
us covariate, exp() is interpreted as the OR associ-
ted with a 1-unit increase in the covariate.
Sometimes the number of events may be either
ery low or very high relative to the sample size.
his may occur when looking at engraftment at day
8 for matched sibling allogeneic transplantations,
hen almost all transplant recipients engraft by that
ime. In this case, it may be more appropriate to use
xact logistic regression [12], which does not rely on
arge sample size approximations to determine the P
alues.
Next we discuss the second scenario, in which
ensoring is present and the researcher is interested in
he entire cumulative incidence curve. Recently a lot
f work has been done on direct modeling for the
umulative incidence functions, rather than for the
rude hazard function [13-16]. Klein and Andersen
13] model the cumulative incidence function for in- t
B&MTividual i at a time t, Cit, through a transformation or
ink function g(x). The model is given by
g(Cit)tZit,
here Zit denotes the covariate vector for subject i at
ime t. Note that this model encompasses time-depen-
ent covariates through Zit but requires that a grid or
eries of time points be speciﬁed. Usually 5 to 10 time
oints sufﬁce to adequately model the cumulative in-
idence function. The regression estimator of the pa-
ameter vector  is based on pseudovalues from the
umulative incidence function. First, compute the cu-
ulative incidence function at time t for the complete
ata set, denoted Cˆt, and the cumulative incidence
unction on the data set obtained by deleting patient i,
enoted by Cˆt
(i). Then the pseudovalue estimate of
it, the cumulative incidence for subject i at time t, is
iven by the difference
Cˆit nCˆt (n 1)Cˆti
hen there is no censoring, Cˆit reduces to a simple
ndicator of whether the ith subject had experienced
he event by time t.
Once these pseudovalues are computed for each
ndividual and time point on the prespeciﬁed grid,
hey are used as the dependent variables in the model
bove to examine the effects of covariates on outcome.
arameter estimates and standard errors are obtained
y using generalized estimating equations [17] and
ay be computed using the SAS procedure (SAS In-
titute, Cary, NC) GENMOD, for example.
Although many choices of the link function are pos-
ible, we mention 3 explicitly. First, the logistic link
unction
g(x) log[x ⁄ (1 x)]
ives results analogous to those with logistic regres-
ion, so we can interpret exp() for a binary covariate
s the OR for someone with the factor relative to
omeone without the factor. Second, the complemen-
ary log-log link function
g(x)log[log(1 x)]
s analogous to the usual Cox regression, because this
ink function, when applied to a survival function,
ives a proportional hazards representation. Third, an
dentity link function g(x) x yields an additive model
or the cumulative incidence function as discussed in
lein [14].
Finally, we point out that other methods of di-
ectly modeling the cumulative incidence function are
lso available. Fine [15] used a similar model for the
umulative incidence function, but with a different
stimation technique. Fine and Gray [16] proposed a
odel for the subdistribution hazard of the cumula-ive incidence function.
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1XAMPLES
xample 1: Engraftment
We illustrate the discussed regression models on
ngraftment by using data from a study by Eapen et al.
18]. This article compares the results of 143 periph-
ral blood stem cell (PBSC) and 630 BM transplants
rom HLA-identical sibling donors in children aged 8
o 20 years with acute leukemia by using data reported
o the Center for International Bone and Marrow
ransplant Research. In the BM group, 1 subject had
issing engraftment information, whereas 571 en-
rafted before day 28, thus giving a cumulative inci-
ence of engraftment at day 28 of 571 of 629 (90.8%).
n the PBSC group, 137 of 143 (95.8%) engrafted
efore day 28. All patients who did not engraft sur-
ived at least until day 28. The median time to en-
raftment was 18 and 13 days for the BM and PBSC
roups, respectively. No patient was lost to follow-up
n the ﬁrst 28 days, so logistic regression is appropri-
te. Figure 1 shows the cumulative incidence of neu-
rophil engraftment as a function of time.
Multivariate regression models were considered to
ompare engraftment between PBSC and BM after
djusting for important patient, disease, or transplant
haracteristics. Factors considered included the recip-
ent’s age, performance score, status with respect to
ytomegalovirus, type of leukemia, and disease status
t transplantation; the sex of the recipient and donor;
he year of transplantation; the conditioning regimen;
he type of prophylaxis against graft-versus-host dis-
ase (GVHD); and the use or nonuse of growth factor
ithin the ﬁrst 7 days of allograft infusion to hasten
eutrophil recovery. After model selection, the ﬁnalFigure 1. Cumulative incidence of
10ox model adjusted for use of growth factor, GVHD
rophylaxis, and donor-recipient sex matching. These
esults were essentially unchanged when the engraft-
ent time was censored at 28 days. The logistic re-
ression model found no factors signiﬁcantly related
o outcome. The results of the Cox model gave a
elative risk (95% conﬁdence interval [CI]) of rate of
ngraftment for PBSC versus BM of 2.25 (1.85-2.72),
ith a P value of .001, thus indicating a large effect
f stem cell source on the rate of engraftment. How-
ver, the logistic regression gave an OR (95% CI) for
ngraftment by day 28 of 2.32 (0.98-5.48), with a
value of .055, thus suggesting no effect of PBSCs on
he cumulative incidence of engraftment at day 28.
hen the factors found to be signiﬁcant in the Cox
odel (growth factors [P  .66], GVHD prophylaxis
P  .25], and sex matching [P  .74] in the extended
ogistic model) were added to the logistic model, the
value for the PBSC effect was 0.0894 (OR, 2.11;
5% CI, 0.89-5.02), so the discrepancy was not due to
he effect of any omitted covariates. The reason for this
iscrepancy is apparent when viewing the cumulative
ncidence curves in Figure 1, which shows that the curves
eparate but come back together. This means that almost
verybody engrafts, but patients receiving PBSCs en-
raft at a faster rate. Therefore, it is important for in-
estigators to use a regression technique appropriate to
he clinical objective, whether it is identifying differences
n rate of engraftment (Cox model) or identifying
ifferences in the incidence of engraftment at a clin-
cally meaningful time by logistic regression or other
umulative incidence models. From the analysis, we
an conclude that PBSC patients engraft faster butengraftment for example 1.
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Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities
Bhat by 28 days, the proportion who have engrafted is
he same in both groups.
xample 2: Cumulative Incidence of Relapse
We illustrate the discussed regression models for
he cumulative incidence of relapse by using an Inter-
ational Bone Marrow Transplant Registry study of
lternative donor BM transplants reported in Szydlo
t al. [19] and discussed in Klein and Andersen [13].
he study consisted of 1715 patients receiving a BM
ransplant from an HLA-identical sibling donor (n 
224), an HLA-matched unrelated donor (n  383),
r an HLA-mismatched unrelated donor (n  108).
he main objective of the study was to compare re-
apse and treatment-related mortality between pa-
ients with different donor types. Here we focus on
elapse as the event of interest, with treatment-related
ortality as the competing risk. Diseases included
ere acute lymphoblastic leukemia (537 cases), acute
yelogenous leukemia (340 cases), and chronic my-
logenous leukemia (838 cases). Patients underwent
ransplantation in varying stages of disease according
o their remission status, including early (1026 cases),
Figure 2. Cumulative inc
able 1. Results of the Cox Regression Analysis on the Risk of Relapse a
f Relapse
Donor Type*
Cox Regression
 SE () RR (
atched unrelated .01 .15 1.01 (
ismatched unrelated .94 .36 0.39 (
R indicates relative risk.
Relative to the matched sibling donor baseline group.
B&MTntermediate (410 cases), or advanced (279 cases). The
nitial Karnofsky performance score was 90 in 1382
ases.
Figure 2 shows the cumulative incidence of relapse
s a function of time. Note that the Kaplan-Meier
stimator is not an appropriate measure of the prob-
bility of relapse. It is estimating this probability in
atients who cannot die. It overestimates the relapse
robability as well (eg, at 3 years in the sibling donor
roup, the cumulative incidence was 0.2036, and the
aplan-Meier estimator was 0.2504). Two types of
egression models adjusted for disease, disease stage,
nd Karnofsky score were ﬁt to the data. Table 1
ontains the results of the Cox model for the rate of
elapse and the pseudovalue technique for modeling
he cumulative incidence of relapse directly. For the
atter, the complementary log-log link function was
sed with a grid of 10 time points, which were equally
paced on an event scale. For the comparison of mis-
atched unrelated and matched sibling donor groups,
oth models indicated a signiﬁcant difference between
roups. However, for the comparison of matched un-
elated and matched sibling donor groups, different
of relapse for example 2.
Pseudovalue Regression Analysis on the Cumulative Incidence
Pseudovalue Model
) P Value  SE () P Value
6) .94 .37 .16 .023
9) .01 1.61 .45 <.001nd the
Model
95% CI
0.75-1.3
0.19-0.7111
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1esults appeared. There was no signiﬁcant difference
etween matched unrelated and matched sibling do-
ors in the risk of relapse with the Cox model (relative
isk, 1.01; 95% CI, 0.75-1.36). By using the pseudo-
alue technique to model the cumulative incidence of
elapse directly, there was a signiﬁcant difference (P
023); this indicates that recipients of matched unrelated
onor transplants had a signiﬁcantly lower cumulative
ncidence of relapse than recipients of matched sibling
onor transplants. This result matches the cumulative
ncidence curves in Figure 2 better than the results of the
ox model.
It is also important to consider the source of the
iscrepancy between the 2 models. The Cox model
onsiders the instantaneous risk of relapse among peo-
le who are still at risk of relapsing or dying. It tells us
hat among yesterday’s disease-free survivors, there is
o evidence of a difference in the chance of relapsing
oday between patients with a matched sibling or
atched unrelated donor. Because there are differ-
nces in the risk of treatment-related mortality be-
ween these 2 groups (RR, 2.25; 95% CI, 1.86-2.72
omparing matched unrelated versus matched sibling
onor transplants), different numbers of patients are
t risk of relapse over time in the 2 groups. These
ifferential risk sets are implicitly incorporated when
irectly modeling the cumulative incidence function,
hereas the Cox model considers only the risk of
elapse among those still at risk. Thus, the regression
odel for the cumulative incidence function tells us
hat there is a difference in the chance that a patient
as relapsed before any day between the matched
ibling and unrelated groups. In fact, patients with
atched sibling donors are approximately 1.5  e0.37
imes more likely to have relapsed before any time
han a similar patient with a matched unrelated donor.
ONCLUSIONS
We have reviewed several alternative regression
odels that may be useful in analyzing stem cell trans-
lantation data with competing risks. It is important
o note that these models focus on different aspects of
he time-to-event distribution, such as the instanta-
eous risk of the event occurring or the cumulative
ncidence probability. Because they model different
uantities, these models may lead to different treat-
ent comparison results, as demonstrated in our ex-
mples. The choice of the appropriate technique re-
uires the investigator to clarify the quantity of interest.
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